



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Theodore Laetsch, M.D.

Committee: Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

Meeting Date: June 17-18, 2020

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda items:

On June 17, 2020, information will be presented regarding pediatric development plans for two products that are in development for an adult oncology indication. The subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of written requests for pediatric studies, if appropriate. The two products under consideration are: (1) SP 2577 application presentation by Salarius Pharmaceuticals, Inc. and (2) Marizomib, application presentation by Celgene International II Sàrl, a wholly owned subsidiary of Bristol-Myers Squibb; and on June 18, 2020, information will be presented regarding pediatric development plans for two products that are in development for an adult oncology indication. The subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of written requests for pediatric studies, if appropriate. The two products under consideration are: (1) CD30.CAR-T, application presentation by Tessa Therapeutics and (2) SNDX-5613, application presentation by Syndax Pharmaceuticals, Inc., I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
contract/grant	Children’s Oncology Group (COG), unrelated entity	(b) (4) per year to University of Texas Southwestern (UTSW)  \$10,000 - \$25,000 per year in salary support to Dr. Laetsch
contract/grant	Novartis, potentially competing firm	(b) (4) per year
contract/grant	Neuroblastoma and Medulloblastoma Translational	(b) (4) per year

	Research Consortium, unrelated entity	
contract/grant	Eisai, potentially competing firm	(b) (4) per year
contract/grant	Onyx Pharmaceuticals, potentially competing firm	(b) (4) per year
contract/grant	Novartis, potentially competing firm	(b) (4) per year to UTSW \$0 - \$10,000 per year in salary support to Dr. Laetsch
contract/grant	Children's Hospital of Los Angeles (CHLA), unrelated entity	(b) (4) per year
contract/grant	Abbvie, potentially competing firm	(b) (4) per year
contract/grant	(b) (4), potentially competing firm	(b) (4) per year
contract/grant	Janssen Research and Development, potentially competing firm	(b) (4) per year
contract/grant	Novartis, potentially competing firm	(b) (4) per year
contract/grant	CHLA, unrelated entity	(b) (4) per year
contract/grant	CHLA, unrelated entity	(b) (4) per year
contract/grant	(b) (4) potentially competing firm	\$(b) (4) per year, estimated
contract/grant	(b) (4), potentially competing firm	\$(b) (4) per year, estimated

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/s/\_\_\_\_\_  
Signature

6/01/20\_\_\_\_\_  
Date